Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Manelimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lodapolimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Isecarosmab, an antibody targeting ADAMTSL5 × Albumin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gatralimab, an antibody targeting CD52.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cudarolimab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alsevalimab, an antibody targeting VTCN1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vixtimotamab, an antibody targeting CD3E × SIGLEC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ponsegromab, an antibody targeting GDF15.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pelgifatamab, an antibody targeting PSMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pavurutamab, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pacanalotamab, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obrindatamab, an antibody targeting B7-H3 × CD3E.